drugset / Trial / NCT06208280
F01 in the Treatment of Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open lable clinical study to evaluate the safety and tolerability of F01 in autoimmune diseases.
Timeline
- Start
- 2024-01-09
- Primary completion
- 2025-01
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F01 | Cell therapy | 5e+08 cells | — |
| Subject | F01 | Cell therapy | 3e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |